header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

Research

OSTEOBLAST-SPECIFIC MICRORNA-29A AMELIORATES OESTROGEN LOSS-INDUCED OSTEOPOROSIS

European Orthopaedic Research Society (EORS) 2015, Annual Conference, 2–4 September 2015. Part 1.



Abstract

Background

MicroRNAs are non-coding small RNAs that reportedly regulate mRNA targets or protein translation of various tissues in physiological and pathological contexts. This study was undertaken to characterise the contributions of microRNA-29a (miR-29a) to the progression of estrogen deficiency-mediated excessive osteoclast resorption and bone loss.

Methods

Osteoblast-specific transgenic mice overexpressing miR-29a driven by osteocalcin promoter (C57BL/6JNarl-TgOCN-mir29a) or wild-type mice were subjected to bilateral ovariectomy. Bone mineral density, trabecular microarchitecture and osteoclast distribution was quantified by μCT and histomorphometry. Primary CD11b+CSF-1R+ preosteoclasts were isolated for detecting ex vivo osteoclast differentiation. Gene expression and transcription factor-promoter interaction were quantified by RT-PCR and chromatin immunoprecipitation.

Results

Estrogen depletion deteriorated bone integrity in concomitant with decrement of miR-29a expression. Transgenic mice had increased bone mass and skeletal microstructure and mitigated responses to the deleterious effects of estrogen deficiency on bone mineral density, B.Ar/T.Ar, Tb.Th and Tb.No. miR-29a overexpression attenuated the estrogen loss-mediated histopathology of osteoclast number, surface and erosion surface. Ex vivo, miR-29a transgenic mice had decreased osteoclast differentiation, osteoclastogenic marker expression (osteoclastogenic transcription factor NFATc1, TRAP, MMP-9, cathepsin K, and V-ATPase), F-actin ring and pit formation of primary preosteoclast cells. miR-29a alleviated the estrogen deficiency-induced promotion of interleukin-17 (IL-17) expression and enrichment of suppressor of cytokine signaling 2 (SOCS2) and signal transducer and activator of transcription 4 (STAT4) on IL-17 proximal promoter regions.

Conclusions

Estrogen deficiency-mediated interruption of miR-29a expression exacerbates bone tissue resorption. miR-29a signalling via suppression of proinflammatory cytokine IL-17 action counteracts osteoclast differentiation and resorption reactions, thereby attenuates the deleterious effect of estrogen loss on bone integrity. This study highlights the skeletal-protective actions of miR-29a against excessive bone remodelling. Sustained miR-29a in bone tissue is beneficial for ameliorating osteoporosis.

Level of evidence

II